EXHIBIT 11.2
SONUS PHARMACEUTICALS, INC.
COMPUTATION OF PRO FORMA NET INCOME (LOSS) PER SHARE
Three Months Ended Nine Months Ended
September 30, 1995 September 30, 1995
------------------ ------------------
Net loss ....................................................................... $(1,947,175) $(2,838,157)
Add interest on deferred revenue ............................................... 76,412 204,913
----------- -----------
$(1,870,763) $(2,633,244)
=========== ===========
Weighted average shares outstanding ............................................ 1,952,864 1,963,843
Weighted average common shares giving effect to the
conversion of preferred stock into common stock for
all periods subsequent to issuance ........................................... 2,352,219 2,352,219
Net effect of stock options exercised and stock options
and warrants granted during the 12 months prior to the Company's filing of its
initial public offering calculated using the treasury stock method at the
offering price of $7 per share, and treated as outstanding for all periods
prior to the closing of the initial public offering .......................... 97,196 97,730
Weighted average common shares giving effect to the
conversion of the convertible subordinated debenture
into common stock using the initial public offering
price of $7 per share ........................................................ 462,857 462,857
Weighted average common shares giving effect to the
conversion of $3.6 million of deferred revenue from
the time of receipt, plus accrued interest at the initial
public offering price of $7 per share ........................................ 547,249 524,099
----------- -----------
Shares used in computation of pro forma net loss per
share ........................................................................ 5,412,385 5,400,748
=========== ===========
Pro forma net loss per share ................................................... $ (0.35) $ (0.49)
=========== ===========
13